Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy

Bibliography

• FU JY, MASFERRER JL, SIEBERT K, RAZ A, NEEDLEMAN P: The induction of prostaglandin-112 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. (1990) 265:16737–16747.
   PubMed Web of Science ®Google Scholar
• •This paper was the first to describe compelling evidence of the existence of a second isoform of cyclooxygenase.
   Google Scholar
• JONES DA, CARLTO DP, MCINTYRE TM, ZIMMERMAN GA, PRESCOTT SM: Molecular cloning of human prosta-glandin synthase Type II and demonstration of expression in response to cytokines. J. Biol. Chem. (1997) 268:9049–5054.
   Google Scholar
• HERSCHMAN HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. (1994) 13:241–256.
   PubMed Web of Science ®Google Scholar
• SEIBERT K, ZHANG Y, LEAHY K et al: Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc. Natl. Acad. ScL USA (1994) 91:12013–12017.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, ISAKSON PC, SEIBERT K: Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointes-tinal tract. Gastroenterol. Clin. North Am. (1996) 25:363–372.
   PubMed Web of Science ®Google Scholar
• PENNING TD, TALLEY JJ, BERTENSHAW SR et al.:Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibi-tors: identification of 445 (4-methylpheny0-3-(trifluoromethyl)-1H-pyrazol-1-ylibenzenesulfona-mide (SC-58635, celecoxib). J. Med. Chem. (1997) 40:1347–1365.
   PubMed Web of Science ®Google Scholar
• CHAN CC, BOYCE S, BRIDEAU C et al.: Rofecoxib [Vioxx,MK-0966; 4- (4'-methylsulfonylpheny1)-3-phenyl-2- (51-1)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol Exp. Ther.(1999) 290:551–560.
   PubMed Web of Science ®Google Scholar
• SMITH JC, ZHANG Y, KOBOLDT CM et al.: Pharma-cological analysis of cyclooxygenase-1 in inflamma-tion. Proc. Natl. Acad. Sci. USA (1998) 95:13313–13318.
   PubMed Web of Science ®Google Scholar
• SIMON LS, LANZA FL, LIPSKY PE et al.: Preliminary studyof the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum (1998) 41(9):1591–602.
   PubMed Web of Science ®Google Scholar
• •Important report of the potent anti-inflammatory properties of COX-2 inhibitors and their relative safety in comparison to NSAIDs.
   Google Scholar
• GEIS GS: Update on clinical developments withcelecoxib, a new specific COX-2 inhibitor: what can we expect?j Rheumatol. (1999) 56:31–36.
   Google Scholar
• FORT J: Celecoxib, a COX-2 specific inhibitor: theclinical data. Am. J. Orthop. (1999) 28 (Suppl. 3):13–8.
   Google Scholar
• SEED MP: Angiogenesis inhibition as a drug target fordisease: an update. Exp. Opin. Invest. Drugs. (1996) 5(12):1617–1637.
   Google Scholar
• FORM DM, AUERBACH R: PGE2 and angiogenesis. Proc.Soc. Exp. Biol. Med. (1983) 172(2):214–218.
   PubMed Web of Science ®Google Scholar
• ROLLAND PH, MARTIN PM, JACQUEMEIER J, ROLLANDAM, TOGS M: Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Institute (1980) 64:1061–1070.
   PubMed Web of Science ®Google Scholar
• KARMALI RA, WELTS S, THALER HT, LEFEVRE F: Prosta-glandins in breast cancer: relationship to disease stage and hormone status. Br. J. Cancer (1983) 48:689–696.
   PubMed Web of Science ®Google Scholar
• FULTON AM, OWNBY HE, FREDERICK J, BRENNAN MJ:Relationship of tumor prostaglandin levels to early recurrence in women with primary breast cancer: a clinical update. Invasion Metastasis (1986) 6:83–94.
   PubMedGoogle Scholar
• BENNETT A, BERSTOCK DA, RAJA B, STANFORD IF: Survival time after surgery is inversely related to amounts of prostaglandin extracted from human breast cancer. Br. J. Pharmacol (1979) 66:451P.
   PubMed Web of Science ®Google Scholar
• PUGH S, THOMAS GA: Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut (1994) 35:675–678.
   PubMed Web of Science ®Google Scholar
• RIGAS B, GOLDMAN IS, LEVINE L: Altered eicosanoidlevels in human colon cancer. J. Lab. Clin. Med. (1993) 122:518–523.
   PubMed Web of Science ®Google Scholar
• YANG VW, SHIELDS JM, HAMILTON SR et al.: Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. (1998) 58:1750–1753.
   PubMed Web of Science ®Google Scholar
• KINZLER KW, VOGELSTEIN B: Lessons from hereditary colorectal cancer. Cell (1996) 87:159–170.
   PubMed Web of Science ®Google Scholar
• GRIDLEY G., MCLAUGHLIN JK, EKBOM A et al.: Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst. (1993) 85:307–311.
   PubMed Web of Science ®Google Scholar
• SANDLER RS: Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Lippincott-Raven Publishers Philadel-phia, PA (1996).
   Google Scholar
• SUH 0, METTLIN C, PETRELLI NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer (1993) 72:1171–1177.
   PubMed Web of Science ®Google Scholar
• MARNETT LJ: Aspirin and related nonsteroidalanti-inflammatory drugs as chemopreventive agents against colon cancer. Preventive Med. (1995) 24:103–106.
   PubMed Web of Science ®Google Scholar
• REEVES MJ, NEWCOMB PA, TRENTHAM-DIETZ A, STORERBE, REMINGTON PL: Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer EpidemioL Biomark. Prey. (1996) 5:955–960.
   PubMed Web of Science ®Google Scholar
• ROSENBERG L, PALMER JR, ZAUBER GA, WARSHAUER ME, STOLLEY PD, SHAPIRO S: A hypothesis: nonster-oidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J. Natl. Cancer Inst. (1991) 83:355–358
   PubMed Web of Science ®Google Scholar
• PELEG II, MAIBACH HT, BROWN SH, WILCOX CM: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. (1994) 121:394–399.
   Google Scholar
• MUSCAT JE, STELLMAN SD, WYNDER EL: Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer (1994) 74:1847–1854.
   PubMed Web of Science ®Google Scholar
• MORGAN G: Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut (1996) 38:646–648.
   PubMed Web of Science ®Google Scholar
• THUN MJ, NAMBOODIRI MM, CALLE EE, FLANDERS WD, HEATH CW JR: Aspirin use and risk of fatal cancer. Cancer Res. (1993) 53:1322–1327.
   PubMed Web of Science ®Google Scholar
• •A large prospective study that clearly demonstrated reduced risk of colon cancer in both men and women.
   Google Scholar
• SCHREINEMACHERS DM, EVERSON RB: Aspirin use and lung, colon, and breast cancer incidence in a prospec-tive study. Epidemiology (1994) 5:138–146.
   PubMed Web of Science ®Google Scholar
• MCCORMICK DL: Inhibition of mammary carcino-genesis by flurbiprofen, a non-steroidal antiinflamma-tory agent. Br. J. Cancer (1983) 48:859–861.
   PubMed Web of Science ®Google Scholar
• HARRIS RE, NAMBOODIRI KK, FARRAR WB: Nonsteroidalantiinflammatory drugs and breast cancer. Epidemi-ology (1996) 5:138-146. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
   Google Scholar
• HARRIS RE, NAMBOODIRI KK, FARRAR WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemi-ology (1996) 7:203–205.
   PubMed Web of Science ®Google Scholar
• HARRIS RE, NAMBOODIRI KK, FARRAR WB: Epidemiol-ogical study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol. Rep. (1995) 2:591–592.
   PubMed Web of Science ®Google Scholar
• •One of the first epidemiological reports extending the relationship between NSAID use and cancer to other major human cancers.
   Google Scholar
• THUN MJ: NSAID use and decreased risk of gastrointes- tinal cancers. Gastroenterol. Clin. North America (1996) 25:333–348.
   PubMed Web of Science ®Google Scholar
• FARROW DC, VAUGHAN TL, HANSTEN PD et al.: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epid. Biom. Prey. (1998) 7:97–102.
   PubMed Web of Science ®Google Scholar
• FUNKHOUSER EM, SHARP GB: Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 76:1116–1119.
   PubMed Web of Science ®Google Scholar
• GIOVANNUCCI E, EGAN KM, HUNTER DJ et al.: Aspirin and the risk of colorectal cancer in women. NewEngl. J. Med. (1995) 333:609–614.
   PubMed Web of Science ®Google Scholar
• GIOVANNUCCI E, RIMM EB, STAMPFER MJ, COLDITZ GA; ASCHERIO A, WILLETT WC: Aspirin use and the risk for colorectal cancer and adenoma in male health profes-sionals. Ann. Intern. Med. (1994) 121:241–246.
   PubMed Web of Science ®Google Scholar
• GIARDIELLO FM, OFFERHAUS JA, TERSMETTE AC et al.: Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut (1996) 38:578–581.
   PubMed Web of Science ®Google Scholar
• GIARDIELLO FM, HAMILTON SR, KRUSH AJ et al.: Treatment of colonic. and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl. J. Med. (1993) 328:1313–1316.
   Google Scholar
• WADDEL WR, LOUGHRY RW: Sulindac for polyposis coli. j Surg. Oncol (1983) 24:83–87.
   PubMed Web of Science ®Google Scholar
• LABAYLE D., FISHER D, VIELN P et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 101:635–639.
   Google Scholar
• WOLFE MM, LICHTENSTEIN DR, SINGH G: Gatrointes-tinal toxicity of non-steroidal anti-inflammatory drugs. New Engl. J. Med. (1999) 340 (24) :1888–1899.
   PubMed Web of Science ®Google Scholar
• REDDY BS, RAO CV, SEIBERT K: Evaluation of cyclooxygenase-2 inhibito for potential chemopre-ventive properties in colon carcinogenesis. Cancer Res. (1996) 56:4566–4569.
   PubMed Web of Science ®Google Scholar
• •First report to demonstrate reduced polyp formation in the AOM mouse by a COX-2 selective inhibitor, and suggest that previously reported efficacy of NSAIDs are due to their ability to inhibit COX–2.
   Google Scholar
• KAWAMORI T, RAO CV, SEIBERT K, REDDY BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcino-genesis. Cancer Res. (1998) 58:409–412.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, FUKUTAKE M, YOKOTA S, ISHIDA K, WAKABAYASHI K, SUGIURA T: Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimelsulide, a selective inhibitor of cyclooxygenase-2. J. Cancer Res. Clin. Oncol (1996) 122:219–222.
   PubMed Web of Science ®Google Scholar
• YOSHIMI N, KAWABATA K, HARA A: Inhibitory effect ofNS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res. (1997) 88:1044–1051.
   PubMedGoogle Scholar
• JACOBY RF, MARSHALL DJ, NEWTON MA: Chemopre-vention of spontaneous intestinal adenomas in the APCmin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. (1996) 56:710–714.
   PubMed Web of Science ®Google Scholar
• BARNES CJ, LEE M: Chemoprevention of spontaneousintestial adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroeneterology (1998) 114:873–878.
   PubMed Web of Science ®Google Scholar
• JACOBY RF, COLE CE, SEIBERT K, KELLOFF G, LUBETTRA: The specific cyclooxygenase-2 inhibitor, celecoxib, causes adenoma regression in the APC mutant Min mouse model. American Assoc. Cancer Res. Ming (1997) Late Breaking Session.
   Google Scholar
• •This study demonstrated a COX-2 inhibitor could be efficaceous when dosed after tumour initiation, and caused unusual regression in residual tumours. In contrast to all other NSAIDS previously tested in this model, the COX-2 inhibitor did not cause morbidity or gastrointestinal ulcera-tion at effective chemopreventive doses, and drug plasma levels were similar to that obtained in human clinical trials.
   Google Scholar
• NAKATSUGI S, FUKUTAKE M, TAKAHASHI M et al: Suppression of intestinal polyp development by nimelsulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn. J. Cancer Res. (1997) 88:1117–1120.
   PubMedGoogle Scholar
• OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Suppres-sion of intestinal polyposis in APC-delta-716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 87:803–809.
   PubMed Web of Science ®Google Scholar
• •This report provided key genetic evidence on the role of COX-2 in colon carcinogenesis, and clearly demonstrated that COX-2 plays a critical, rate-limiting step during adenoma formation.
   Google Scholar
• FISCHER SM, LO HH, GORDON GB et al.: Chemopreven-tive actvity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Molecular Carcinogenesis (1999) 25:231–240.
   PubMed Web of Science ®Google Scholar
• MOON RC, KELLOFF GJ, DETRISAC CJ, STEELE VE, THOMAS CF, SIGMAN CC: Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis (1993) 14:1487–1489.
   PubMed Web of Science ®Google Scholar
• RAO KVN, DETRISAC CJ, STEELE VE, HAWK ET, KELLOFF GJ, MCCORMICK DL: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis (1996) 17:1435–1438.
   PubMed Web of Science ®Google Scholar
• OKAJIMA E, OZONO S, ENDO T et al.: Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and B-carotene on the development of rat urinary bladder carcinoma after N-butyl-N- (4-hydroxybutyl) nitrosamine-induce d © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10) bladder carcinogenesis in rats. Jpn. J. Cancer Res. (1997) 88:543–552.
   Google Scholar
• OKAJIMA E, DENDA A, OZONO S et al: Chemopreven-tive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybuty0 nitrosamine. Cancer Res. (1998) 58:3028–3031.
   PubMed Web of Science ®Google Scholar
• FULTON AM, LEVY JG: Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin. Int. J. Cancer (1980) 26:669–673.
   PubMed Web of Science ®Google Scholar
• CARTER CA, MILHOLLAND RJ, SHEA W, IP MM: Effect of prostaglandin synthase inhibitor indomethacin on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res. (1983) 43:3559–3562.
   PubMed Web of Science ®Google Scholar
• MCCORMICK DL, MOON RC: Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br. J. Cancer (1983) 48:859–861.
   PubMed Web of Science ®Google Scholar
• FULTON AM: In-vivo effects of indomethacin on the growth of murine mammmary tumor. Cancer Res., (1984) 44:2416–2420.
   PubMed Web of Science ®Google Scholar
• MCCORMICK DL, MADIGAN MJ, MOON RC: Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. (1985) 45:1803–1808.
   PubMed Web of Science ®Google Scholar
• WILSON KT, FU S, RAMANUJAM KS, MELTZER SJ: Increased expression of inducible nitric oxide and cyclooxygenase -2 in Barrett's esophagus and associ-ated adenocarcinomas. Cancer Res. (1998) 58:2929–2934.
   PubMed Web of Science ®Google Scholar
• SOSLOW RA, DANNENBERG AJ, RUSH D et al: COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer (1999) (In Review).
   Google Scholar
• EBERHART CE, COFFEY RJ, RADHIKA A et al.: Upregula-tion of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroen-terology (1994) 107:1183–1188.
   PubMed Web of Science ®Google Scholar
• HIDA T, TAYABE Y, ACHIWA H et al.: Increased expres-sion of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. (1998) 58:3761–3764.
   PubMed Web of Science ®Google Scholar
• MOHAMMED SI, KNAPP DW, BOSTWICK DG: Expression of cyclooxygenase-2 in human invasive transitional cell carcinoma of the urinary bladder. Cancer Res. (1999) (In Press).
   Google Scholar
• BUCKMAN SY, GRESHAM A, HALE P et al: COX-2 expres-sion is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis (1998) 19(5)723–729.
   Google Scholar
• KNAPP DW, RICHARDSON RC, BOTTOMS GD, TECLAW R,CHAN TCK: Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chem other. Pharmacol (1992) 29:214–218.
   PubMed Web of Science ®Google Scholar
• KNAPP DW, RICHARDSON RC, CHAN TCK: Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Interrn. Med. (1994) 8:273–278.
   PubMed Web of Science ®Google Scholar
• •This was one of the first reports demonstrating NSAIDS can be effective as a chemotherapeutic agent, and may act synergistically when used in conjuction with traditional cytotoxic agents.
   Google Scholar
• KNAPP DW, GLICKMAN NW, DENICOLA DB, BONNEY PL, LIN TL, GLICKMAN LT: Naturally-occurring canine transitional cell carcinoma of the urinary bladder, a relevant model of human invasive bladder cancer. Urol. Oncol (1999) (In Press).
   Google Scholar
• MOHAMMED S, LAFAYETTE W, FOSTER R et al.: Expres-sion of cyclooxygenase COX-1 and COX-2 in human invasive transitional cell carcinoma of the urinary bladder. American Urological Association Meeting, Dallas, TX (1999)
   Google Scholar
• LUNDHOLM K, GELIN J, HYLTANDER A, LONNROTH C, SANDSTROM R, SVANIGER G: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. (1994) 5:5602–5606.
   Google Scholar
• •One of the first and only studies which evaluated the effect of anti-inflammatory treatment on tumour progression in clinical cancer. Survival analysis demonstrated indometha-cin can significantly prolong survival, and was the first to show NSAIDS may have utility as chemotherapeutic agents.
   Google Scholar
• CHAN G, BOYLE JO, YANG EK et al.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. (1999) 59: 991–994.
   PubMed Web of Science ®Google Scholar
• TUCKER ON, DANNENBERG AJ, YANG EK et al.: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. (1999) 59:987–990.
   PubMed Web of Science ®Google Scholar
• KUTCHERA W, JONES DA, MATSUNAMI N: Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA (1996) 93:4816–4820.
   PubMed Web of Science ®Google Scholar
• HWANG D, SCOLLARD D, BYRENE J, LEVINE E: Expres-sion of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Insti. (1998) 90:455–460.
   PubMed Web of Science ®Google Scholar
• PARRETT ML, HARRIS RE, JOARDER FS, ROSS MS,CLAUSEN KP, ROBERTSON FM: Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol (1997) 10:503–507.
   PubMed Web of Science ®Google Scholar
• WOLFF H, SAUKKONEN KL, ANTTILA S, KARJALAINEN A,VAINIO H, RISTIMAKI A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. (1998) 58:4997–5001.
   PubMed Web of Science ®Google Scholar
• TOYOAKI H, YATABE Y, ACHIWA H et al.: Increasedcyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. (1998) 58:3761–3764.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN KC, SARBIA M, WEBER A, BORCHARD F, GABBERT H, SCHROR K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. (1999) 59:198–204.
   PubMed Web of Science ®Google Scholar
• RISTIMAKI A, HONKANEN N, JANKALA H, SIPPONEN P,HARKONEN M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. (1997) 57:1276-1280. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
   Google Scholar
• MCGOUGH KA, JACKSON JR, MINTON JA, MARSHALL LA,JACOBS RS, WINKLER JD: Inflammatory PGE2 produc-tion is maintained during hypoxia in rheumatoid synovial fibroblasts. Inflamm. Res. (1997) 2:S147.
   Google Scholar
• HABIB A, CREMINON C, FROBERT Y et al: Demonstra-tion of an inducible cyclooxygenase in human endothelial cells using antibody raised against the carboxyl-terminal region of cyclooxygenase-2. J. Biol. Chem. (1993) 23:23448–23454.
   Google Scholar
• CREMINON C, HABIB A, MACLOUF J et al.: Differentialmeasurement of constitutive COX-2 expression in human umbilical vein endothelial cells using specific immmunometric enzyme immunoassays. Biochem. Biophys. Acta (1995) 1254:341–348.
   PubMed Web of Science ®Google Scholar
• SZCZEPANSKI A, MOATTER T, CARLEY WW, GERRITSENME: Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1. Inhibi-tion by glucocorticoids. Arthritis Rheum. (1994) 37:495–503.
   PubMed Web of Science ®Google Scholar
• AKARASEREENONT P, MITCHELL JA, THIMMERMAN C etal.: Comparison of the inducible enzyme of cyclooxy-genase and nitric oxide in endothelial cells and macrophages. Eur. J. Pharmacol. (1995) 273:141–148.
   Google Scholar
• TSUJII M, KAWANO S, TSUJI S, SAWAOKA H, HORI M, DUBOIS RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1 9 9 8) 29:93(5) :705–716.
   Google Scholar
• KALGUTKAR AS, CREWS BC, ROWLINSON SW et al.: Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science (1998) 280:1268–1270.
   PubMed Web of Science ®Google Scholar
• KENYON BA, VOEST EE, CHEN EF, FOLKMAN J, D'AMATORJ: A model of angiogenesis in the mouse cornea. Invest. Opthamol Visual Sci. (1995) 37:1625–1632.
   Web of Science ®Google Scholar
• MASFERRER JL, SETTLE S, ZWEIFEL BS et al.: COX-2 inhibitors: A new class of antiangiogenic agents. Proc. Ann. Meet. Am. Assoc. Cancer Res. (1998) 1885:271.
   Google Scholar
• FORM DM, AUERBACH R: PGE2 and angiogensis. Proc. Soc. Exp. Biol. Med. (1983) 172:214–218.
   PubMed Web of Science ®Google Scholar
• MARNETT U. Generation of mutagens during arachi-donic acid metabolism. Cancer Metastasis Rev. (1994) 13:303–308.
   PubMed Web of Science ®Google Scholar
• ELING TE, CURTIS JF: Xenobiotic metabolism byprostglandin H synthase. Pharmacol. Ther. (1992) 53;261–263.
   PubMed Web of Science ®Google Scholar
• MARNETT LJ, REED GA, DENNISON DJ: Prostaglandin synthetase dependent activation of 7,8-dihydro-7,8-dihydroxy-benzo[a]pyrene to mutagenic derivatives. Biochem. Biophys Res. Commun. (1978) 82:210–216.
   PubMed Web of Science ®Google Scholar
• GUTHRIE J, ROBERTSON IGC, ZEIGER E et al.: Selectiveactivation of some dihydrodiols of several polycyclic aromatic hydrocarbons to mutagenic products by prostaglandin synthetase. Cancer Res. (1 98 2) 42:1620-1623.
   Google Scholar
• KADLUBAR FF, FREDERICK CB, WEIS CC et al.: Prosta-glandin endoperoxide synthetase-mediated metabo-lism of carcinogenic aromatics amines and their binding to DNA and protein. Biochem. Biophys. Res. Commun. (1982) 108:253–258.
   PubMed Web of Science ®Google Scholar
• SUBBARAMAIAH K, ZAKIM D WEKSLER BB et al.: Inhibi-tion of cyclooxygenase: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med. (1997) 216:201–210.
   PubMed Web of Science ®Google Scholar
• DENISSENKO MF, PAO A, TUNG MS et al.: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot spots in p53. Science (1996) 274:430–432.
   PubMed Web of Science ®Google Scholar
• LEE FD: Importance of apoptosis in the histopathology of drug-related lesions in the large intestine. J. Clin. Pathol (1993) 46:118–122.
   PubMed Web of Science ®Google Scholar
• PASRICHA PJ, BEDI A, O'CONNER K et al.: The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology (1995) 109:994–998.
   Google Scholar
• ELDER DJ, HAGUE A, HICKS DJ, PARASKEVA C: Differen-tial growth inhibition by the aspirin metabolite salicy-late in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in in-vitro transformed adenoma relative to adenoma cell lines. Cancer Res. (1996) 56:2273–2276.
   PubMed Web of Science ®Google Scholar
• PIAZZA GA, RAHM ALK, JRUTZCH M etal.: Antineoplastic drugs sulindac sulfide and suldindac sulfone inhibit cell growth by inducing apoptosis. Cancer Res. (1995) 1195:3110–3116.
   Google Scholar
• SHIFF SJ, QIA0 L, TSAI LL, RIGAS B: Suldindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell-cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. (1995) 96:491–503.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA R, ICHII S, HASHIMOTO T, FURUYAMA JI, UTSONOMIYA J: Effect of aspirin on the induction of apoptosis in adenocarcinoma cell lines. Oncol Rep. (1995) 2:361–364.
   PubMed Web of Science ®Google Scholar
• BATTU S, RIGAUD M, BENEYTOUT JL: Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line 11T29 CL.19A. Anti Cancer Res. (1998) 18 (5A):3579–3583.
   Google Scholar
• SUBBEGOWDA R, FROMMEL TO: Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res. (1998) 1:58 (13):2772–2776.
   Google Scholar
• GOLUBOFF ET, SHABSIGH A, SAIDI JA et al.: Exisuland (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology (1999) 53 (2) 440–445.
   PubMed Web of Science ®Google Scholar
• SAWAOKA H, KAWANO S, TSUJI S, TSUJI' M, MURATA H, HORI M: Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J. Clin. Gastroenterol. (1998) 27(S1)1:S47–52.
   Google Scholar
• TSUJII M, DUBOIS RN: Alterations in cellular adehision and apoptosis in epithelial-cells overexpressing prostaglandin-endoperoxide synthase-2. Cell (1995) 83:493–501.
   PubMed Web of Science ®Google Scholar
• •One of the first reports to strongly implicate that COX-2 may play a pivotal role in apoptosis and adhesion during carcinogenesis.
   Google Scholar
• DUBOIS RN, SHAO J, TSUJII M, SHENG H, BEAUCHAMP RD: Gi delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. (1996) 56: 733–737.
   PubMed Web of Science ®Google Scholar
• BOOLBOL SK, DANNENBERG AJ, CHADBURN A et al: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. (1996) 56:2556–2560.
   PubMed Web of Science ®Google Scholar
• SHENG H, SHAO J, MORROW JD, BEAUCHAMP RD, DUBOIS RN: Modulation of apoptosis and Bc1-2 expres-sion by prostaglandin E2 in human colon cancer cells. Cancer Res. (1996) 58:362–366.
   Web of Science ®Google Scholar
• SHENG H, SHAO J, KIRKLAND SC et al: Inhibition of human colon cancer cell growth by selective inhibi-tion of cyclooxygenase-2. J. Clin. Invest. (1997) 99:2254–2259.
   PubMed Web of Science ®Google Scholar
• LIU XH, YAO S, KIRSCHENBAUM A, LEVINE AC: NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bc1-2 expression in LNCaP cells. Cancer Res. (1998) 1:58 (19):4245–4259.
   Google Scholar
• TSUJI M, KAWANA S, DUBOIS RN: Cyclooxygenase-2 expression in human colon cancer cells increase metastatic potential. Proc. Nati Acad. Sci. USA (1997) 94:3336–3340.
   PubMed Web of Science ®Google Scholar
• MARNETT L: Aspirin and the potential role of prosta-glandins in colon cancer. Cancer Res. (1992) 52:5575–5780.
   PubMed Web of Science ®Google Scholar
• ERICKSON BA, LONGO WE, PANESAR N, MAZUSKI JE, KAMINSKI DL: The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res. (1999) 81(1):101–107.
   PubMed Web of Science ®Google Scholar
• SAWAOKA H, KAWANO S, TSUJI S et al.: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physic)]. (1998) 274(6 Pt 1):G1061–1067.
   Google Scholar
• RIENDEAU D, PERCIVAL MD, BOYCE S et al.: Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. (1997) 121:105–117.
   PubMed Web of Science ®Google Scholar
• BRIDEAU C, KARGMAN S, LIU S et al: A human whole blood assay for clinical evaluatioin of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. (1996) 45:68–74.
   PubMed Web of Science ®Google Scholar
• PIZZA GA, ALBERTS DS, HIXSON JL et al.: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. (1997) 57:2909–2915.
   PubMed Web of Science ®Google Scholar
• MAHMOUD NN, BOOLBOOL SK, DANNENBERG AJ et al.: The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogen esis (1998) 19:87–91.
   PubMed Web of Science ®Google Scholar
• RAO CV, RIVENSON A, SIMI B et al.: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. (1995) 55:1464–1472.
   PubMed Web of Science ®Google Scholar
• WILLIAMS CS, SHATTUCK-BRANDT RL, DUBOIS RN: The role of COX-2 in intestinal cancer. Exp. Opin. Invest. Drugs (1999) 8:1–12.
   PubMedGoogle Scholar
• PETERSON S, PETERSEN C, KISHI K et al.: COX-2 inhibitor enhances tumor radioresponse in vitro and in vivo. Eicosanoids & Other Bioactive Lipids in Cancer, Inflamma-tion, & Related Diseases (1999) :A11.
   Google Scholar
• PENNING TD, TALLEY JJ, BERTENSHAW SR et al.: Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibi-tors: Identification of 445-(4-methylpheny0-3 -(trifluoromethyl)-1H-pyrazol-1-ylibenzenesulfona-mide (SC-58635, Celecoxib). J. Med. Chem. (1997) 40:1347–1365.
   PubMed Web of Science ®Google Scholar